Trial Profile
A Pilot Study of a Personalized Neoantigen Cancer Vaccine With and Without Low-Dose Cyclophosphamide in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated Chronic Lymphocytic Leukemia
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 20 Apr 2023
Price :
$35
*
At a glance
- Drugs NEO-PV 01 (Primary) ; Cyclophosphamide; Pembrolizumab; Poly ICLC
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions; First in man; Pharmacodynamics; Therapeutic Use
- 17 Apr 2023 Planned End Date changed from 31 Mar 2025 to 31 Mar 2028.
- 17 Apr 2023 Planned primary completion date changed from 31 Mar 2023 to 31 Mar 2026.
- 20 Sep 2021 Status changed from not yet recruiting to recruiting.